Arcellx, Inc. (ACLX)Â
NASDAQ
Market Cap
$3.59B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
511 of 950
Rank in Industry
276 of 543
Largest Insider Buys in Sector
ACLX Stock Price History Chart
ACLX Stock Performance
About Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Activity of Arcellx, Inc.
Over the last 12 months, insiders at Arcellx, Inc. have bought $0 and sold $74.71M worth of Arcellx, Inc. stock.
On average, over the past 5 years, insiders at Arcellx, Inc. have bought $182.5M and sold $67.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 312,500 shares for transaction amount of $5M was made by BASKETT FOREST () on 2022‑06‑21.
List of Insider Buy and Sell Transactions, Arcellx, Inc.
| 2025-01-14 | Sale | director | 1,500 0.0028% | $65.87 | $98,801 | +3.65% | ||
| 2025-01-08 | Sale | SEE REMARKS | 13,837 0.0259% | $73.69 | $1.02M | 0.00% | ||
| 2025-01-08 | Sale | CHIEF MEDICAL OFFICER | 3,553 0.0066% | $73.69 | $261,831 | 0.00% | ||
| 2025-01-08 | Sale | CHIEF FINANCIAL OFFICER | 3,997 0.0075% | $73.69 | $294,551 | 0.00% | ||
| 2025-01-07 | Sale | SEE REMARKS | 16,474 0.03% | $75.53 | $1.24M | -13.03% | ||
| 2025-01-07 | Sale | CHIEF MEDICAL OFFICER | 4,230 0.0077% | $75.53 | $319,485 | -13.03% | ||
| 2025-01-07 | Sale | CHIEF FINANCIAL OFFICER | 14,012 0.0255% | $75.68 | $1.06M | -13.03% | ||
| 2025-01-06 | Sale | SEE REMARKS | 15,111 0.0287% | $77.17 | $1.17M | -10.43% | ||
| 2025-01-06 | Sale | CHIEF MEDICAL OFFICER | 2,975 0.0056% | $77.17 | $229,571 | -10.43% | ||
| 2025-01-06 | Sale | CHIEF FINANCIAL OFFICER | 5,621 0.0107% | $77.17 | $433,755 | -10.43% | ||
| 2025-01-03 | Sale | SEE REMARKS | 15,112 0.0284% | $79.55 | $1.2M | -14.87% | ||
| 2025-01-03 | Sale | CHIEF MEDICAL OFFICER | 2,975 0.0056% | $79.55 | $236,656 | -14.87% | ||
| 2025-01-03 | Sale | CHIEF FINANCIAL OFFICER | 5,622 0.0106% | $79.55 | $447,219 | -14.87% | ||
| 2024-12-24 | Sale | director | 1,500 0.0028% | $76.97 | $115,451 | 0.00% | ||
| 2024-12-03 | Sale | director | 1,500 0.0028% | $91.88 | $137,818 | -10.86% | ||
| 2024-11-15 | Sale | CHIEF FINANCIAL OFFICER | 1,761 0.003% | $88.87 | $156,508 | -5.94% | ||
| 2024-11-12 | Sale | director | 1,500 0.0029% | $106.33 | $159,495 | -17.21% | ||
| 2024-11-11 | Sale | director | 15,238 0.0283% | $105.92 | $1.61M | -21.69% | ||
| 2024-11-08 | Sale | director | 7,976 0.0142% | $99.85 | $796,426 | -19.06% | ||
| 2024-11-08 | Sale | CHIEF FINANCIAL OFFICER | 12,354 0.0222% | $100.55 | $1.24M | -19.06% |
Insider Historical Profitability
29%
| Carroll Jill | director | 1479148 2.7354% | $66.48 | 1 | 6 | +6.58% |
| Elghandour Rami | SEE REMARKS | 117275 0.2169% | $66.48 | 0 | 11 | |
| Heery Christopher | CHIEF MEDICAL OFFICER | 25085 0.0464% | $66.48 | 0 | 36 | |
| Gilson Michelle | CHIEF FINANCIAL OFFICER | 9582 0.0177% | $66.48 | 0 | 13 | |
| Ware Olivia C | director | 0 0% | $66.48 | 0 | 2 | |
| Patel Kavita | director | 0 0% | $66.48 | 0 | 15 | |
| New Enterprise Associates 15, L.P. | 10 percent owner | 6745262 12.474% | $66.48 | 2 | 0 | +40.21% |
| Novo Holdings A/S | 10 percent owner | 4016878 7.4284% | $66.48 | 1 | 0 | +6.58% |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1658780 3.0676% | $66.48 | 1 | 1 | +6.58% |
| SANDELL SCOTT D | director | 0 0% | $66.48 | 0 | 2 | |
| BASKETT FOREST | director | 0 0% | $66.48 | 1 | 1 | +73.84% |
| Florence Anthony A. Jr. | director | 0 0% | $66.48 | 0 | 1 | |
| Makhzoumi Mohamad | director | 0 0% | $66.48 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Fidelity Investments | $375.19M | 10.08 | 5.39M | +23.18% | +$70.62M | 0.03 | |
| Perceptive Advisors | $273.58M | 7.35 | 3.93M | -13.45% | -$42.51M | 0.18 | |
| Paradigm BioCapital Advisors LP | $265.55M | 7.14 | 3.82M | +4.36% | +$11.09M | 9.63 | |
| Nea Management Company Llc | $260.48M | 7 | 3.75M | 0% | +$0 | 1.22 | |
| BlackRock | $213.25M | 5.73 | 3.07M | +1.57% | +$3.31M | 0.01 | |
| Sr One Capital Management Lp | $163.21M | 4.39 | 2.35M | -25.42% | -$55.64M | 44.83 | |
| The Vanguard Group | $155.02M | 4.17 | 2.23M | +8.1% | +$11.62M | <0.01 | |
| State Street | $131.11M | 3.52 | 1.89M | +6.27% | +$7.74M | 0.01 | |
| Cormorant Asset Management Lp | $123.8M | 3.33 | 1.78M | +4.71% | +$5.56M | 5.77 | |
| Suvretta Capital Management, LLC | $108.66M | 2.92 | 1.56M | -35.86% | -$60.76M | 4.59 | |
| Janus Henderson | $105.86M | 2.85 | 1.52M | -1.03% | -$1.11M | 0.05 | |
| T. Rowe Price | $93.51M | 2.51 | 1.34M | +6.7% | +$5.87M | 0.01 | |
| Lord Abbett | $83.33M | 2.24 | 1.2M | +0.13% | +$107,802.45 | 0.29 | |
| T Rowe Price Investment Management Inc | $68.36M | 1.84 | 982,862 | +6.55% | +$4.21M | 0.04 | |
| Geode Capital Management | $58.32M | 1.57 | 838,469 | +6.76% | +$3.69M | 0.01 | |
| Morgan Stanley | $48.46M | 1.3 | 696,762 | +3.49% | +$1.63M | <0.01 | |
| JPMorgan Chase | $38.37M | 1.03 | 551,750 | -8.33% | -$3.49M | <0.01 | |
| Samsara Biocapital Llc | $31.55M | 0.85 | 453,641 | -1.48% | -$472,940.01 | 4.92 | |
| Deutsche Bank | $31.14M | 0.84 | 447,783 | +221.71% | +$21.46M | 0.01 | |
| Bank of America | $28.83M | 0.78 | 414,541 | +113.36% | +$15.32M | <0.01 | |
| Voya Investment Management LLC | $26.45M | 0.71 | 380,323 | +366.81% | +$20.79M | 0.03 | |
| Voloridge Investment Management, LLC | $25.25M | 0.68 | 363,093 | +54.01% | +$8.86M | 0.09 | |
| Northern Trust | $25M | 0.67 | 359,460 | -1.09% | -$275,487.55 | <0.01 | |
| PFM Health Sciences | $21.09M | 0.57 | 303,210 | -9.54% | -$2.22M | 0.58 | |
| Great Point Partners | $20.86M | 0.56 | 300,000 | +521.58% | +$17.51M | 3.5 | |
| Affinity Asset Advisors | $20.86M | 0.56 | 300,000 | -11.77% | -$2.78M | 0.32 | |
| Charles Schwab | $19.61M | 0.53 | 282,010 | +6.75% | +$1.24M | <0.01 | |
| Goldman Sachs | $18.97M | 0.51 | 272,793 | -23.31% | -$5.77M | <0.01 | |
| Adage Capital Partners Gp L L C | $18.92M | 0.51 | 272,009 | -18.29% | -$4.24M | 0.04 | |
| Ubs Asset Management Americas Inc | $18.46M | 0.5 | 265,410 | +103.95% | +$9.41M | 0.01 | |
| Integral Health Asset Management Llc | $17.74M | 0.48 | 255,000 | +59.38% | +$6.61M | 1.78 | |
| Bamco | $17.32M | 0.47 | 248,993 | +292.12% | +$12.9M | 0.05 | |
| Victory Capital Management Inc | $16.4M | 0.44 | 235,866 | +51.53% | +$5.58M | 0.02 | |
| Federated Hermes | $16.11M | 0.43 | 231,661 | +7.95% | +$1.19M | 0.04 | |
| HERITAGE ASSET MANAGEMENT INC | $15.04M | 0.42 | 224,534 | New | +$15.04M | 0.08 | |
| Candriam S C A | $15.3M | 0.41 | 220,008 | -21.99% | -$4.31M | 0.1 | |
| Russell Investments Group Ltd | $13.59M | 0.37 | 195,437 | +3.11% | +$409,998.02 | 0.02 | |
| Two Sigma | $13.13M | 0.35 | 188,854 | +30% | +$3.03M | 0.02 | |
| Nuveen | $12.99M | 0.35 | 186,783 | -33.2% | -$6.46M | <0.01 | |
| Parkman Healthcare Partners Llc | $10.89M | 0.29 | 156,598 | -6.93% | -$811,231.21 | 1.36 | |
| Soleus Capital Management, L.P. | $10.43M | 0.28 | 150,000 | -5.66% | -$625,950.00 | 0.04 | |
| Rafferty Asset Management Llc | $8.82M | 0.24 | 126,751 | +13.22% | +$1.03M | 0.03 | |
| Squarepoint Ops LLC | $8.42M | 0.23 | 121,011 | -6.31% | -$566,484.75 | 0.03 | |
| BNY Mellon | $8.42M | 0.23 | 121,064 | -8.24% | -$756,008.57 | <0.01 | |
| Citigroup | $7.99M | 0.22 | 114,947 | +119.65% | +$4.35M | 0.01 | |
| Woodline Partners LP | $7.24M | 0.19 | 104,060 | 0% | +$0 | 0.06 | |
| UBS | $7.2M | 0.19 | 103,481 | +6.63% | +$447,623.77 | <0.01 | |
| Qube Research & Technologies | $7.04M | 0.19 | 101,186 | +626.65% | +$6.07M | 0.01 | |
| Walleye Capital | $6.55M | 0.18 | 94,208 | -20.39% | -$1.68M | 0.02 | |
| Td Asset Management Inc | $6.25M | 0.17 | 89,918 | +10.58% | +$598,130.01 | 0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.